Loading stock data…
NovoCure Limited (NVCR)
$17.65-2.34 (-11.71%)
Market ClosedLast close Jul 24
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NovoCure Limited in the Healthcare sector is trading at $17.65 with a market capitalization of $1.9B. Wall Street consensus targets $27.14 (7 analysts), implying a +53.8% move over the next 12 months. The stock is currently 18% below its 52-week high of $21.45, remaining 28.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +53.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $174.06M↓ | $174.35M↑ | $167.20M↑ | $158.81M↑ | $154.99M |
| Gross Profit | $135.13M↑ | $132.19M↑ | $122.47M↑ | $117.33M↑ | $116.47M |
| Operating Income | -$67.42M↓ | -$40.39M↓ | -$36.02M↑ | -$39.52M↓ | -$37.87M |
| Net Income | -$71.14M↓ | -$24.50M↑ | -$37.27M↑ | -$40.14M↓ | -$34.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.32%
Volume
Today's trading volume
3.87M
Recent News
NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds
NovoCure (NVCR) drew fresh investor attention after raising its 2026 net revenue guidance to a range of US$710 million to US$725 million, following a quarter of record sales and active patient growth. See our latest analysis for NovoCure. The recent guidance upgrade and record quarter come after a sharp swing in sentiment around NovoCure, with the stock gaining 41.54% on a 3 month share price return and 46.59% on a 1 year total shareholder return. However, longer term total shareholder...
Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today?
Investors rewarded strong execution, improving profits and raised outlook.
Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes
Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval for its brain therapy candidate. In intra-day trading, the stock climbed to a record high of $20.55 before trimming gains to end the session […]
Novocure Flashes A Bullish Signal As It Breaks Out. Have Shares 'Turned A Corner?'
Novocure stock broke out Thursday after reporting Street-beating, double-digit sales growth for its wearable cancer treatment, Optune.
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?
The medical device maker, which develops Tumor Treating Fields (TTFields) therapy for cancer, said Q2 marked its strongest performance to date.